LLY Q3 2025 Revenue Soars 54%, Exceeding Expectations and Boosting Full-Year Outlook

Eli Lilly and Company (LLY.US) reported robust financial results for the third quarter of 2025, with revenue climbing to $17.60 billion, a significant 54% increase compared to Q3 2024. Non-GAAP diluted earnings per share reached $7.02, surpassing analyst estimates of $6.02 for the quarter.

This strong performance was primarily fueled by substantial volume growth from key products Mounjaro and Zepbound. The company’s increased profitability and strong product demand led to an upward revision of its full-year 2025 financial guidance.

Strong Product Performance Drives Revenue Growth

The impressive revenue growth in Q3 2025 was largely driven by the outstanding performance of Mounjaro and Zepbound, which are key products in Lilly's portfolio. Worldwide Mounjaro revenue surged 109% to $6.52 billion, reflecting strong demand in both U.S. and international markets.

Similarly, U.S. Zepbound revenue experienced a substantial increase of 184%, reaching $3.57 billion. These products were central to the 62% increase in overall volume during the quarter, underscoring their critical role in the company’s financial success.

Management Raises Full-Year Guidance Amidst Pipeline and Manufacturing Progress

Following the strong third-quarter results, Eli Lilly has increased its full-year 2025 revenue guidance to a range of $63.0 billion to $63.5 billion. Non-GAAP EPS guidance has also been raised to a range of $23.00 to $23.70, reflecting the robust business performance and positive foreign exchange impacts.

The company highlighted significant pipeline momentum, including positive Phase 3 trial results for orforglipron in type 2 diabetes and obesity, with plans for global regulatory submissions by year-end. Furthermore, Lilly announced the U.S. FDA approval of Inluriyo (imlunestrant) for certain breast cancer patients and detailed plans for new manufacturing facilities in Virginia and Texas, alongside an expansion of its existing Puerto Rico site, to boost capacity.